File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: A double-blind placebo-controlled randomized trial with immunological monitoring

TitleThe use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: A double-blind placebo-controlled randomized trial with immunological monitoring
Authors
KeywordsChemotherapy
Immune function
Ovarian cancer
Quality of life
Traditional Chinese medicine
Issue Date2011
PublisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/
Citation
Annals Of Oncology, 2011, v. 22 n. 10, p. 2241-2249 How to Cite?
AbstractBackground: This study aimed to evaluate traditional Chinese medicine (TCM) in improving quality of life (QOL), reducing chemotoxicity and modulating immune function in patients undergoing chemotherapy. Patients and methods: Patients with ovarian cancer were randomized to receive either TCM or placebo in addition to standard chemotherapy. The primary outcome was global health status (GHS) score, assessed by European Organization for Research and Treatment of Cancer questionnaire, while the secondary outcomes were other QOL items, chemotoxicity according to World Health Organization criteria and alterations in immune function as measured by immune cells count and the numbers of cytokines-secreting cells. Results: There was no significant difference in the GHS between the two groups. With adjustment for stage, chemotherapy type, disease status, age and baseline value, emotional function, cognitive function and nausea and vomiting were found to be worse or less improved in the TCM group compared with placebo group after six cycles of chemotherapy. The TCM group had less neutropenia after three cycles (0% grade 4 neutropenia versus 28.6%). There were no other significant differences in terms of chemotoxicity. Lymphocyte counts and cytokine activities decreased less in the TCM group. Conclusions: TCM did not improve QOL but did have some effects in terms of maintaining immune function. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/135674
ISSN
2015 Impact Factor: 9.269
2015 SCImago Journal Rankings: 4.362
ISI Accession Number ID
Funding AgencyGrant Number
Tung Wah group of hospitals, Hong Kong
Chinese medicine
Funding Information:

This work was supported by Tung Wah group of hospitals, Hong Kong, and the Chinese medicine and placebo used in this project were donated by Purapharm International (H.K.) Ltd. in support of the services of Tung Wah group of hospitals.

References

 

DC FieldValueLanguage
dc.contributor.authorChan, KKLen_HK
dc.contributor.authorYao, TJen_HK
dc.contributor.authorJones, Ben_HK
dc.contributor.authorZhao, JFen_HK
dc.contributor.authorMa, FKen_HK
dc.contributor.authorLeung, CYen_HK
dc.contributor.authorLau, SKen_HK
dc.contributor.authorYip, MWen_HK
dc.contributor.authorNgan, HYSen_HK
dc.date.accessioned2011-07-27T01:39:11Z-
dc.date.available2011-07-27T01:39:11Z-
dc.date.issued2011en_HK
dc.identifier.citationAnnals Of Oncology, 2011, v. 22 n. 10, p. 2241-2249en_HK
dc.identifier.issn0923-7534en_HK
dc.identifier.urihttp://hdl.handle.net/10722/135674-
dc.description.abstractBackground: This study aimed to evaluate traditional Chinese medicine (TCM) in improving quality of life (QOL), reducing chemotoxicity and modulating immune function in patients undergoing chemotherapy. Patients and methods: Patients with ovarian cancer were randomized to receive either TCM or placebo in addition to standard chemotherapy. The primary outcome was global health status (GHS) score, assessed by European Organization for Research and Treatment of Cancer questionnaire, while the secondary outcomes were other QOL items, chemotoxicity according to World Health Organization criteria and alterations in immune function as measured by immune cells count and the numbers of cytokines-secreting cells. Results: There was no significant difference in the GHS between the two groups. With adjustment for stage, chemotherapy type, disease status, age and baseline value, emotional function, cognitive function and nausea and vomiting were found to be worse or less improved in the TCM group compared with placebo group after six cycles of chemotherapy. The TCM group had less neutropenia after three cycles (0% grade 4 neutropenia versus 28.6%). There were no other significant differences in terms of chemotoxicity. Lymphocyte counts and cytokine activities decreased less in the TCM group. Conclusions: TCM did not improve QOL but did have some effects in terms of maintaining immune function. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.en_HK
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/en_HK
dc.relation.ispartofAnnals of Oncologyen_HK
dc.subjectChemotherapyen_HK
dc.subjectImmune functionen_HK
dc.subjectOvarian canceren_HK
dc.subjectQuality of lifeen_HK
dc.subjectTraditional Chinese medicineen_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - adverse effects - therapeutic use-
dc.subject.meshDrugs, Chinese Herbal - adverse effects - therapeutic use-
dc.subject.meshOvarian Neoplasms - drug therapy - immunology-
dc.subject.meshCarboplatin-
dc.subject.meshMonotherapy-
dc.titleThe use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: A double-blind placebo-controlled randomized trial with immunological monitoringen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0923-7534&volume=&spage=&epage=&date=2011&atitle=The+use+of+Chinese+herbal+medicine+to+improve+quality+of+life+in+women+undergoing+chemotherapy+for+ovarian+cancer:+a+double-blind+placebo-controlled+randomized+trial+with+immunological+monitoringen_US
dc.identifier.emailChan, KKL: kklchan@hkucc.hku.hken_HK
dc.identifier.emailYao, TJ: tjyao@hkucc.hku.hken_HK
dc.identifier.emailNgan, HYS: hysngan@hkucc.hku.hken_HK
dc.identifier.authorityChan, KKL=rp00499en_HK
dc.identifier.authorityYao, TJ=rp00284en_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/annonc/mdq749en_HK
dc.identifier.pmid21355071-
dc.identifier.scopuseid_2-s2.0-80053134302en_HK
dc.identifier.hkuros186754en_US
dc.identifier.hkuros202229-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80053134302&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume22en_HK
dc.identifier.issue10en_HK
dc.identifier.spage2241en_HK
dc.identifier.epage2249en_HK
dc.identifier.eissn1569-8041-
dc.identifier.isiWOS:000295168500011-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChan, KKL=8655666700en_HK
dc.identifier.scopusauthoridYao, TJ=7401886444en_HK
dc.identifier.scopusauthoridJones, B=7404958958en_HK
dc.identifier.scopusauthoridZhao, JF=53464501100en_HK
dc.identifier.scopusauthoridMa, FK=53463614500en_HK
dc.identifier.scopusauthoridLeung, CY=7402612388en_HK
dc.identifier.scopusauthoridLau, SK=36882453400en_HK
dc.identifier.scopusauthoridYip, MW=53464550400en_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats